Email this article 
Exploration du rôle des infirmières en oncologie dans les programmes de dépistage du cancer du col de l’utérus en ces temps de transition
Abstract
Cervical cancer remains the fourth most prevalent cancer among women worldwide, with approximately 660,000 new diagnoses and 350,000 deaths recorded in 2022. Countries with well-established preventative measures have experienced significant reductions in cervical cancer rates through vaccination and regular screening. In Canada, recent efforts have emphasized the adoption of primary HPV-DNA testing as a primary screening tool in cervical cancer screening programs, replacing the cytology (pap) testing. The COVID-19 pandemic had disrupted these initiatives, posing challenges to screening and vaccination programs. Despite these setbacks, ongoing recovery strategies are underway to mitigate the pandemic’s adverse effects. Several challenges regarding this shift also have been identified by countries that have transitioned their respective screening programs to primary HPV-DNA testing. Understanding these unique challenges will be essential for developing strategies to address barriers, such as implementing new technologies, training healthcare providers, and ensuring equitable access to screening. This review seeks to (1) examine the evolution of HPV testing and the transition from cervical cytology (Pap smear) to HPV testing as the primary screening method; (2) assess the long-term impacts of the COVID-19 pandemic on screening, prevention, and HPV vaccination within the Canadian healthcare system; and (3) explore the pivotal role of oncology nurses in advancing education, advocacy, and leadership in cancer prevention.
Full Text:
PDFReferences
Aitken, C. A., Kaljouw, S., Siebers, A. G., Bron, M., Morssink, A., van Kemenade, F. J., & de Kok, I. M. C. M. (2021). Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics. Preventive Medicine Reports, 22, 101328. https://doi.org/10.1016/j.pmedr.2021.101328
Alliance for Cervical Cancer Prevention. (2002, October). Cervical cancer prevention: Fact sheet. International Agency for the Research on Cancers. https://screening.iarc.fr/doc/RH_pap_smears.pdf
American Cancer Society, Inc. (2023, January 12). Cervical cancer statistics: Key facts about cervical cancer. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html#:~:text=Cervical%20cancer%20is%20most%20frequently,still%20present%20as%20they%20age.
Arbyn, M., Gultekin, M., Morice, P., Nieminen, P., Cruickshank, M., Poortmans, P., Kelly, D., Poljak, M., Bergeron, C., Ritchie, D., Schmidt, D., Kyrgiou, M., Van den Bruel, A., Bruni, L., Basu, P., Bray, F., & Weiderpass, E. (2021). The European response to the WHO call to eliminate cervical cancer as a public health problem. International Journal of Cancer, 148(2), 277–284. https://doi.org/10.1002/ijc.33189
Arbyn, M., Xu L., Simoens, C., & Martin-Hirsch, P. P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Systematic Reviews, 2018, 5, Cd009069. https://doi.org/10.1002/14651858.CD009069.pub3
Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Scheneck, U., Segnan, N., Wiener, H., Herbert, A., & von Karsa, L. (2010). European Guidelines for quality assurance in cervical cancer screening: Second Edition – Summary document. Annals of Oncology, 21(3), 448–458. https://doi.org/10.1093/annonc/mdp471
Bains, I., Choi, Y. H., Soldan, K., & Jit, M. (2019). Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 29(4), 669–675. https://doi.org/10.1136/ijgc-2018-000161
Bavor, C., Brotherton, J. M., Smith, M. A., Prang, K. H., McDermott, T., Rankin, N. M., Zammit, C. M., Jennett, C. J., Sultana, F., Machalek, D. A., Nightingale, C. E., & STORIES Team. (2023). The early impacts of primary HPV cervical screening implementation in Australia on the pathology sector: A qualitative study. BMC Health Services Research, 23(1), 1073. https://doi.org/10.1186/s12913-023-10040-6
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M. C., Sy, S., Regan, C., Keane, A., Caruana, M., Nguyen, D. T. N., Smith, M. A., Laprise, J. F., Jit, M., Alary, M., … Hutubessy, R. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet (London, England), 395(10224), 575–590. https://doi.org/10.1016/S0140-6736(20)30068-4
Brotherton, J. M. L., McDermott, T., Smith, M. A., Machalek, D. A., Shilling, H., Prang, K. H., Jennett, C., Nightingale, C., Zammit, C., Pagotto, A., Rankin, N. M., Kelaher, M. (2023). Implementation of Australia’s primary human papillomavirus (HPV) cervical screening program: The Stakeholders Opinions of Renewal Implementation and Experiences Study. Preventative Medicine Reports, 33, 102213. https://doi.org/10.1016/j.pmedr.2023.102213
Bruni, L., Albero, G., Rowley, J., Alemany, L., Arbyn, M., Giuliano, A. R., Markowitz, L. E., Broutet, N., & Taylor, M. (2023). Global and regional estimates of genital human papillomavirus prevalence among men: A systematic review and meta-analysis. The Lancet. Global Health, 11(9), e1345–e1362. https://doi.org/10.1016/S2214-109X(23)00305-4
Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., Velandia-González, M., Pastore, R., Gacic-Dobo, M., & Bloem, P. (2021). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive medicine, 144, 106399 https://doi.org/10.1016/j.ypmed.2020.106399
Canadian Association of Nurses in Oncology. (2001). Standards of care for the generalist, specialized and advanced oncology nurse. Standard 3: Self-determination and decision-making.
Canadian Partnership Against Cancer. (2021). Cervical screening in Canada: 2019/2020 environmental scan. https://s22457.pcdn.co/wp-content/uploads/2021/01/cervical-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf
Canadian Partnership Against Cancer. (2024). Cervical screening in Canada, 2023-24. https://www.partnershipagainstcancer.ca/topics/cervical-screening-canada-2023-2024/modalities/hpv-testing/
Canadian Partnership Against Cancer Corporation. (2023, September 20). Action plan for the elimination of cervical cancer in Canada, 2020–2030. Canadian Partnership Against Cancer. https://www.partnershipagainstcancer.ca/topics/elimination-cervical-cancer-action-plan/
Cappiello, J. D., & Boardman, M. (2018). Longitudinal study of advanced practice nurses’ implementation of screening intervals for cervical cancer screening. Journal of the American Association of Nurse Practitioners, 30(2), 92–100. https://doi.org/10.1097/JXX.000000000000000
Chadwick, V., Bennett, K. F., McCaffery, K. J., Brotherton, J. M., & Dodd, R. H. (2022). Psychosocial impact of testing human papillomavirus positive in Australia’s human papillomavirus-based cervical screening program: A cross-sectional survey. Psycho-Oncology, 31(7), 1110–1119. https://doi.org/10.1002/pon.5897
Chandeying, N., & Thongseiratch, T. (2023). Systematic review and meta-analysis comparing educational and reminder digital interventions for promoting HPV vaccination uptake. NPJ Digital Medicine, 6(1), 162. https://doi.org/10.1038/s41746-023-00912-w
CTV News. (2007, August 18). Health officer refutes coverage of HPV vaccine. https://www.ctvnews.ca/health-officer-refutes-coverage-of-hpv-vaccine-1.253019
Constable, C., Ferguson, K., Nicholson, J., & Quinn, G. P. (2022). Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: A systematic review. CA: A Cancer Journal for Clinicians, 72(6), 561–569. https://doi.org/10.3322/caac.21753
Daniels, V., Saxena, K., Roberts, C., Kothari, S., Corman, S., Yao, L., & Niccolai, L. (2021). Impact of reduced human papillomavirus vaccination coverage rates due to covid-19 in the United States: A model based analysis. Vaccine, 39(20), 2731–2735. https://doi.org/10.1016/j.vaccine.2021.04.003
de Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer, 141(4), 664–670. https://doi.org/10.1002/ijc.30716
Delpero, E., & Selk, A. (2022). Shifting from cytology to HPV testing for cervical cancer screening in Canada. Canadian Medical Association Journal, 194(17). https://doi.org/10.1503/cmaj.211568
Dijkstra, M. G., van Zummeren, M., Rozendaal, L., van Kemenade, F. J., Helmerhorst, T. J., Snijders, P. J., Meijer, C. J., & Berkhof, J. (2016). Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ (Clinical Research Ed.), 355, i4924. https://doi.org/10.1136/bmj.i4924
Dike, S., Cesario, S. K., Malecha, A., & Nurse, R. (2023). An education intervention to increase human papillomavirus vaccination confidence and acceptability: A randomized controlled trial. Oncology Nursing Forum, 50(4), 423–436. https://doi.org/10.1188/23.ONF.423-436
Feinberg, Y., Pereira, J. A., Quach, S., Kwong, J. C., Crowcroft, N. S., Wilson, S. E., Guay, M., Lei, Y., & Deeks, S. L. (2015). Understanding public perceptions of the HPV vaccination based on online comments to Canadian news articles. PLOS ONE, 10(6). https://doi.org/10.1371/journal.pone.0129587
Feldman, S., Goodman, A., & Peipert, J. F. (2024, August 24). Patient education: Cervical cancer screening (Beyond the Basics). UpToDate. https://www.uptodate.com/contents/cervical-cancer-screening-beyond-the-basics/print
Garett, R., & Young, S. D. (2021). Online misinformation and vaccine hesitancy. Translational Behavioral Medicine, 11(12), 2194–2199. https://doi.org/10.1093/tbm/ibab128
Gates, A., Pillay, J., Reynolds, D., Stirling, R., Traversy, G., Korownyk, C., Moore, A., Thériault, G., Thombs, B. D., Little, J., Popadiuk, C., van Niekerk, D., Keto-Lambert, D., Vandermeer, B., & Hartling, L. (2021). Screening for the prevention and early detection of cervical cancer: Protocol for systematic reviews to inform Canadian recommendations. Systematic Reviews, 10(1). https://doi.org/10.1186/s13643-020-01538-9
Gottschlich, A., van Niekerk, D., Smith, L. W., Gondara, L., Melnikow, J., Cook, D. A., Lee, M., Stuart, G., Martin, R. E., Peacock, S., Franco, E. L., Coldman, A., Krajden, M., & Ogilvie, G. (2021). Assessing 10-year safety of a single negative HPV test for cervical cancer screening: Evidence from FOCAL-decade cohort. Cancer Epidemiology Biomarkers & Prevention, 30(1), 22–29. https://doi.org/10.1158/1055-9965.epi-20-1177
Government of Canada (2022). Vaccination coverage goals and vaccine preventable disease reduction targets by 2025 [Web resource]. Government of Canada; 2018. https://www.canada.ca/en/public-health/services/immunization-vaccine-priorities/national-immunization-strategy/vaccination-coverage-goals-vaccine-preventable-diseases-reduction-targets-2025.html
Government of Canada (2024). Human papillomavirus (HPV) vaccines: Canadian immunization guide for health professionals. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html
Grimes, D. R., Corry, E. M. A., Malagón, T., O’Riain, C., Franco, E. L., & Brennan, D. J. (2021). Modeling cervical cancer screening strategies with varying levels of human papillomavirus vaccination. JAMA Network Open, 4(6), e2115321. https://doi.org/10.1001/jamanetworkopen.2021.15321
Hall, M. T., Simms, K. T., Lew, J. B., Smith, M. A., Brotherton, J. M., Saville, M., Frazer, I. H., & Canfell, K. (2019). The projected timeframe until cervical cancer elimination in Australia: A modelling study. The Lancet. Public Health, 4(1), e19–e27. https://doi.org/10.1016/S2468-2667(18)30183-X
International Agency for Research on Cancer. (2023). Protection from a single dose of HPV vaccine: A major public health impact from IARC studies of vaccine efficacy. IARC Evidence Summary Briefs, No. 4. International Agency for Research on Cancer. https://www.iarc.who.int/evidence-summarybriefs-series/.
International Agency for Research on Cancer Working Group on the Evaluation of Cancer-Preventive Strategies (2005). Cervix cancer screening. Vainio, H., Hakama, M., Bianchini, F., Cheney, J., (Editors). International Agency for Research on Cancer.
International Agency for Research on Cancer Working Group on the Evaluation of Cancer-Preventive Interventions. (2022). Cervical cancer screening. IARC Handbooks of Cancer Prevention, No. 18; ISBN-13: 978-9283230243 (pdf)
Inturrisi, F., Aitken, C. A., Melchers, W. J. G., van den Brule, A. J. C., Molijn, A., Hinrichs, J. W. J., Niesters, H. G. M., Siebers, A. G., Schuurman, R., Heideman, D. A. M., de Kok, I. M. C. M., Bekkers, R. L. M., van Kemenade, F. J., & Berkhof, J. (2021). Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study. The Lancet Regional Health - Europe, 11, 100235. https://doi.org/10.1016/j.lanepe.2021.100235
Jayasinghe, Y., Rangiah, C., Gorelik, A., Ogilvie, G., Wark, J. D., Hartley, S., & Garland, S. M. (2016). Primary HPV DNA-based cervical cancer screening at 25 years: Views of young Australian women aged 16–28 years. Journal of Clinical Virology, 76. https://doi.org/10.1016/j.jcv.2015.10.026
Johnson, C. A., James, D., Marzan, A., & Armaos, M. (2019). Cervical cancer: An overview of pathophysiology and management. Seminars in Oncology Nursing, 35(2), 166–174. https://doi.org/10.1016/j.soncn.2019.02.003
Kim., J. J., Burger, E., Regan, C., & Sy, S. (2018). Screening for cervical cancer in primary care A decision analysis for the US Preventive Services Task Force. JAMA.320(7), 706–714.
Koliopoulos, G., Nyaga V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R., Schunemann, H., Paraskevaidis, E., & Arbyn, M. (2017a). Cytology versus HPV testing for cervical cancer screening in general population Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008587.pub2
Koliopoulos, G., Nyaga V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R., Schunemann, H., Paraskevaidis, E., & Arbyn, M. (2017b). Human papillomavirus (HPV) test compared to the Papanicolaou (Pap) Test to screen for cervical cancer. Cochrane Evidence Systhesis and Methods. Cochrane. https://www.cochrane.org/CD008587/GYNAECA_human-papillomavirus-hpv-test-compared-papanicolaou-pap-test-screen-cervical-cancer
Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G. A., Zhou, Y., & Jin, T. (2021). Epidemiology and burden of Human Papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Frontiers in Public Health, 8, 552028. https://doi.org/10.3389/fpubh.2020.552028
Lin, Y., Hu, Z.,, Alias, H., & Li Ping Wong. (2022). The role of nurses as human papillomavirus vaccination advocates in China: Perception from nursing students, Human Vaccines & Immunotherapeutics, 18, 1, 2030169. https://doi.org/10.1080/21645515.2022.2030169
Maver, P. J., & Poljak, M. (2020). Primary HPV-based cervical cancer screening in Europe: Implementation status, challenges, and future plans. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 26(5), 579–583. https://doi.org/10.1016/j.cmi.2019.09.006
McBride, E., Marlow, L. A. V., Forster, A. S., Ridout, D., Kitchener, H., Patnick, J., & Waller, J. (2019). Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: The psychological impact of primary screening (PIPS) study. International Journal of Cancer, 146(8), 2113–2121. https://doi.org/10.1002/ijc.32540
Meggetto, O., Jembere, N., Gao, J., Walker, M. J., Rey, M., Rabeneck, L., Murphy, K. J., & Kupets, R. (2021). The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: A population-based study. BJOG: An International Journal of Obstetrics & Gynaecology, 128(9), 1503–1510. https://doi.org/10.1111/1471-0528.16741
Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019). Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and Mortality Weekly Report, 68(32), 698–702. https://doi.org/10.15585/mmwr.mm6832a3
National Advisory Committee on Immunization. (2015) Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. An Advisory Committee Statement (ACS). Catalogue Number: HP40-128/2014E-PDF
National Cancer Institute. (2024.). Cervical cancer screening. National Institutes of Health. https://www.cancer.gov/types/cervical/screening
National Cancer Institute. (2019) HPV and cancer. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer.
National Cancer Institute’s PROSPR Consortium, Corley, D. A., Sedki, M., Ritzwoller, D. P., Greenlee, R. T., Neslund-Dudas, C., Rendle, K. A., Honda, S. A., Schottinger, J. E., Udaltsova, N., Vachani, A., Kobrin, S., Li, C. I., & Haas, J. S. (2021). Cancer screening during the coronavirus disease-2019 pandemic: A perspective from the National Cancer Institute’s PROSPR Consortium. Gastroenterology, 160(4), 999–1002. https://doi.org/10.1053/j.gastro.2020.10.030
Nemec, M., Waller, J., Barnes, J., & Marlow, L. A. V. (2022). Acceptability of extending HPV-based cervical screening intervals from 3 to 5 years: An interview study with women in England. BMJ Open, 12(5), e058635. https://doi.org/10.1136/bmjopen-2021-058635
Ogilvie, G. S., Smith, L. W., van Niekerk, D., Khurshed, F., Pedersen, H. N., Taylor, D., Thomson, K., Greene, S. B., Babich, S. M., Franco, E. L., & Coldman, A. J. (2016). Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. BMC Public Health, 16(1). https://doi.org/10.1186/s12889-016-2865-8
Ogilvie, G. S., van Niekerk, D., Krajden, M., Smith, L. W., Cook, D., Gondara, L., Ceballos, K., Quinlan, D., Lee, M., Martin, R. E., Gentile, L., Peacock, S., Stuart, G. C., Franco, E. L., & Coldman, A. J. (2018). Effect of screening with primary cervical HPV testing versus cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV focal randomized clinical trial. Obstetrical & Gynecological Survey, 73(11), 632–634. https://doi.org/10.1097/ogx.0000000000000608
Piché-Renaud, P.-P., Ji, C., Farrar, D. S., Friedman, J. N., Science, M., Kitai, I., Burey, S., Feldman, M., & Morris, S. K. (2021). Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada. Vaccine, 39(31), 4373–4382. https://doi.org/10.1016/j.vaccine.2021.05.094
Polman, N. J., Ebisch, R. M., Heideman, D. A., Melchers, W. J., Bekkers, R. L., Molijn, A. C., Meijer, C. J., Quint, W. G., Snijders, P. J., Massuger, L. F., van Kemenade, F. J., & Berkhof, J. (2019). Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: A randomised, paired screen-positive, non-inferiority trial. The Lancet Oncology, 20(2), 229–238. https://doi.org/10.1016/s1470-2045(18)30763-0
Popadiuk, C., Gauvreau, C. L., Bhavsar, M., Nadeau C., Asakawa, K., Flanagan, W. M., Wolfson, M. C., Coldman, A. J., Memon, S., Fitzgerald, N., Lacombe, J. and Miller, A. B. (2016). Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada. Current Oncology (Toronto, Ont.), 23(Suppl 1), S56–S63.
Proctor, L., Ogilvie, G., Smith, L., & Gentile, L. (2023). Cervix screening program: Program overview. BC Cancer. http://www.bccancer.bc.ca/screening/health-professionals/cervix
Public Health Agency of Canada. (2012, August 27). NACI Statement: HPV vaccine update. Government of Canada. https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2012-38/canada-communicable-disease-report.html#a3-2
Radley, D., Saah, A., & Stanley, M. (2016). Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Human Vaccines & Immunotherapeutics, 12(3), 768–772. https://doi.org/10.1080/21645515.2015.1088616
Reyburn, R., & Russell, F. (2023). Just one dose of HPV vaccine benefits women worldwide. Pursuit. The University of Melbourne. https://pursuit.unimelb.edu.au/articles/just-one-dose-of-hpv-vaccine-
benefits-women-worldwide
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., Berkhof, J., Peto, J., Meijer, C. J., & International HPV Screening Working Group. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet (London, England), 383(9916), 524–532. https://doi.org/10.1016/S0140-6736(13)62218-7
Shin, H., Jeon, S., Cho, I., & Park, H. (2022). Factors affecting human papillomavirus vaccination in men: Systematic review. JMIR Public Health and Surveillance, 8(4), e34070. https://doi.org/10.2196/34070
Silver, M. I., Rositch, A. F., Burke, A. E., Chang, K., Viscidi, R., & Gravitt, P. E. (2015). Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening. Obstetrics and Gynecology, 125(2), 317–329. https://doi.org/10.1097/AOG.0000000000000638
Smith, A., Baines, N., Memon, S., Fitzgerald, N., Chadder, J., Politis, C., Nicholson, E., Earle, C., & Bryant, H. (2019). Moving toward the elimination of cervical cancer: Modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines. Current Oncology, 26(2), 80–84. https://doi.org/10.3747/co.26.4795
Smith, M., Hammond, I., & Saville, M. (2019). Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Research & Practice, 29(2). https://doi.org/10.17061/phrp2921914
Snijjers, P., Verhoefl, V., Arbyn M., Ogilvie, G., Minozzi, S., Banzi, R., van Kemenade, F., Heideman, D., Meijer, C. (2013). High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer, 132, 2223–2236.
Suk, R., Montealegre, J. R., Nemutlu, G. S., Nyitray, A. G., Schmeler, K. M., Sonawane, K., & Deshmukh, A. A. (2019). Public knowledge of human papillomavirus and receipt of vaccination recommendations. JAMA Pediatrics, 173(11), 1099. https://doi.org/10.1001/jamapediatrics.2019.3105
Suk, R., Hong, Y.-R., Rajan, S. S., Xie, Z., Zhu, Y., & Spencer, J. C. (2022). Assessment of US Preventive Services Task Force guideline–Concordant cervical cancer screening rates and reasons for underscreening by age, race and ethnicity, sexual orientation, rurality, and insurance, 2005 to 2019. JAMA Network Open, 5(1). https://doi.org/10.1001/jamanetworkopen.2021.43582
Thomas, T. L. (2016). Cancer prevention: HPV vaccination. Seminars in Oncology Nursing, 32(3), 273–280. https://doi.org/10.1016/j.soncn.2016.05.007
Trevethan, R. (2017). Sensitivity, specificity, and predictive values: Foundations, pliabilities, and pitfalls in research and practice. Frontiers in Public Health, 5. https://doi.org/10.3389/fpubh.2017.00307
US Preventive Services Task Force (2018). Screening for cervical cancer US Preventive Services Task Force Recommendation Statement. JAMA, 320(7), 674–686.
Veijalainen, O., Kares, S., Kotaniemi-Talonen, L., Kujala, P., Vuento, R., Luukkaala, T., Kholová, I., & Mäenpää, J. (2021). Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstetricia et Gynecologica Scandinavica, 100(3), 403–409. https://doi.org/10.1111/aogs.14021
Walker, M. J., Wang, J., Mazuryk, J., Skinner, S.-M., Meggetto, O., Ashu, E., Habbous, S., Nazeri Rad, N., Espino-Hernández, G., Wood, R., Chaudhry, M., Vahid, S., Gao, J., Gallo-Hershberg, D., Gutierrez, E., Zanchetta, C., Langer, D., Zwicker, V., Rey, M., … Yurcan, M. (2022). Delivery of cancer care in Ontario, Canada, during the first year of the COVID-19 pandemic. JAMA Network Open, 5(4). https://doi.org/10.1001/jamanetworkopen.2022.8855
Wright, T. C., Stoler, M. H., Ranger-Moore, J., Fang, Q., Volkir, P., Safaeian, M., & Ridder, R. (2021). Clinical validation of P16/KI-67 dual-stained cytology triage of HPV-positive women: Results from the impact trial. International Journal of Cancer, 150(3), 461–471. https://doi.org/10.1002/ijc.33812
Wilson, S.E., Quach, S., & MacDonald, S.E. (2017). Immunization information systems in Canada: Attributes, functionality, strengths and challenges. A Canadian Immunization Research Network study. Canadian Journal of Public Health = Revue canadienne de sante publique, 107(6), e575–e582.
World Health Organization. (2018). WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. https://www.who.int/news/item/18-05-2018-who-dg-calls-for-all-countries-to-take-action-to-help-end-the-suffering-caused-by-cervical-cancer
World Health Organization. (2024). Cervical cancer. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
World Health Organization. (2021). WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention. https://www.euro.who.int/en/health-topics/noncommunic
Yeh, P. T., Kennedy, C. E., de Vuyst, H., & Narasimhan, M. (2019). Self-sampling for human papillomavirus (HPV) testing: A systematic review and meta-analysis. BMJ Global Health, 4(3). https://doi.org/10.1136/bmjgh-2018-001351
Yusupov, A., Popovsky, D., Mahmood, L., Kim, A. S., Akman, A. E., & Yuan, H. (2019). The nonavalent vaccine: A review of high-risk HPVs and a plea to the CDC. American Journal of Stem Cells, 8(3), 52–64.
Zelli, J., Hum, S., Lofters, A., & Dunn, S. (2022). Clinician acceptability of self-collected human papillomavirus swabs as a primary cervical cancer screening method. Canadian Family Physician, 68(2). https://doi.org/10.46747/cfp.6802e31
Refbacks
- There are currently no refbacks.
